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Abstract: Ovarian cancer is the most lethal gynecological malignancy. Poor overall survival,
particularly for patients with high grade serous (HGS) ovarian cancer, is often attributed to late
stage at diagnosis and relapse following chemotherapy. HGS ovarian cancer is a heterogenous disease
in that few genes are consistently mutated between patients. Additionally, HGS ovarian cancer
is characterized by high genomic instability. For these reasons, personalized approaches may be
necessary for effective treatment and cure. Understanding the molecular mechanisms that contribute
to tumor metastasis and chemoresistance are essential to improve survival rates. One favored model
for tumor metastasis and chemoresistance is the cancer stem cell (CSC) model. CSCs are cells with
enhanced self-renewal properties that are enriched following chemotherapy. Elimination of this
cell population is thought to be a mechanism to increase therapeutic response. Therefore, accurate
identification of stem cell populations that are most clinically relevant is necessary. While many CSC
identifiers (ALDH, OCT4, CD133, and side population) have been established, it is still not clear
which population(s) will be most beneficial to target in patients. Therefore, there is a critical need to
characterize CSCs with reliable markers and find their weaknesses that will make the CSCs amenable
to therapy. Many signaling pathways are implicated for their roles in CSC initiation and maintenance.
Therapeutically targeting pathways needed for CSC initiation or maintenance may be an effective
way of treating HGS ovarian cancer patients. In conclusion, the prognosis for HGS ovarian cancer
may be improved by combining CSC phenotyping with targeted therapies for pathways involved in
CSC maintenance.
Keywords: ovarian cancer; cancer stem cells; signaling; chemoresistance; metastasis
1. Introduction
In the United States, ovarian cancer is the fifth leading cause of cancer death in women [1].
The American Cancer Society (ACS) estimates that this year approximately 22,240 women will be
newly diagnosed with ovarian cancer, and ~14,075 women will die as a result of the disease, making it
the most lethal gynecologic malignancy (ACS Facts and Figures 2018). The vagueness of symptoms
(bloating, abdominal/pelvic pain, difficulty eating/feeling of fullness, and frequent urination) and the
lack of early detection methods contribute to the majority of patients (70–75%) receiving diagnoses in
advanced stages (stage III or stage IV) when the cancer has metastasized throughout the peritoneal
cavity [1,2]. The five-year survival rate for women with advanced-stage ovarian cancer is ~25% [3,4].
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There are several major ovarian cancer subtypes. Additionally, there is mutational and gene
expression heterogeneity within each subgenre. Mutational and gene expression heterogeneity is also
found in different subpopulations within a single tumor. Patients with the same pathological diagnosis,
such as high grade serous (HGS) carcinoma, often vary greatly with respect to gene expression
and specific genetic mutations [3,5,6]. The lack of consistent mutations or mis-expressed genes
makes developing novel targeted therapeutics difficult. The current standard of care is a “one size
fits all” approach consisting of aggressive debulking surgery to resect visible tumor followed by
platinum and taxane combination chemotherapy [1,7–9]. Residual tumor implants measuring less
than 1 cm are considered indicative of optimal debulking [1]. Debulking surgery performed by
a gynecological oncologist improves the chance of survival; however, many patients are not treated
by gynecological oncologists [1,7,8]. Therefore, in some cases, chemotherapy prior to surgery is
equally effective as primary debulking [4]. Chemotherapy treatment is initially effective in 70–80%
of patients [2,10,11]. However, recurrence of the disease will occur in the majority of patients
(80–90%) within 5 years, and the tumors often acquire resistance to the chemotherapeutics [1,9,11].
The presence of microscopic tumors left behind during surgical debulking and the limitations of current
chemotherapeutics contribute to the likelihood of relapse. The presence or enrichment of cancer stem
cells (CSCs), which are defined as tumor cells that survive and/or accumulate after chemotherapy,
have activation of self-renewing signaling pathways, and exhibit increased tumor-initiating properties,
may contribute to relapse [11–13]. We will discuss how CSC properties contribute to chemoresistance
and how investigating these properties may lead to novel therapeutics to eliminate ovarian cancer and
prevent relapse.
2. Histologic Types of Ovarian Cancer
Ovarian tumors are divided into three types: epithelial (60%), germ cell (30%), and specialized
stromal cells tumors (8%) [3,14]. Epithelial tumors comprise the majority of malignant ovarian tumors
(80–90%) [10,14]. Within the epithelial tumors there are four major subtypes: serous, endometrioid,
clear cell, and mucinous [5,15,16]. Serous tumors are the most common of the epithelial subtypes and
comprise two-thirds of all cases [2,3,5,15]. Historically, serous ovarian cancer is classified according
to three different three-tiered systems based on morphology/histology. The three systems are the
FIGO (the International Federation of Gynecology and Obstetrics) system based on architectural
features, the World Health Organization system based on architectural and cytological features, and the
Shimizu/Silverberg system based on architectural features, degree of atypical cytological features, and
mitotic index, with the most common system being the FIGO system [17]. Within the FIGO system,
serous ovarian carcinomas are classified as low grade (Grade 1), intermediate grade (Grade 2), and high
grade (Grade 3) [16]. Historically, low grade and high grade serous ovarian tumors were considered to
be different grades of the same tumor [5]. However, molecular and genetic studies suggest that it is
likely low grade and HGS tumors are distinct diseases with different genetic mutations and different
prognoses [5,15,18]. A newer two-tier system combines the current histopathological classification
system with molecular genetic findings and clinical features. In this system, ovarian tumors are
designated as Type I or Type II [17,19] (Figure 1).
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undefined carcinomas [5,15,18,20]. 
Low grade serous, mucinous, endometrioid, and clear cell carcinomas fall within the Type I 
classification [5]. These tumors arise from endometrial tissue, fallopian tube tissue, germ cells, and 
transitional epithelium [5,14,15,18,21,22]. Type I tumors grow more slowly (are indolent) and are 
considered to be more genetically stable [5,14,20]. Type II tumors typically have a higher disease 
volume throughout the peritoneal cavity and a higher incidence of ascites than Type I tumors[20]. 
They appear to follow a stepwise pattern from a benign precursor to a malignancy with genetic 
changes in specific cell signaling pathways [2]. Type I tumors are predominantly of non-serous type 
[10]. Low grade serous ovarian cancer accounts for approximately 5–10% of all serous ovarian cancers 
[2,10,16]. The most common pathway disrupted in low grade serous ovarian cancer is the mitogen-
activated protein kinase (MAPK) pathway [5,6,16,17]. Specifically, activating mutations in BRAF and 
KRAS are common [2,10,23]. An active MAPK pathway is found in 80% of low grade serous tumors 
as well as in 78% of their putative precursor lesions (borderline tumors) [16]. Other genes/pathways 
that are commonly altered in Type I tumors include PTEN, PI3K, ARID1A, Wnt/β-catenin, and 
ERRB2 [2,6,15,18,20,24,25] (Figure 2). 
 
Figure 2. Pathway for Type I tumor formation. Type I tumors appear to form in a stepwise manner 
from benign precursor lesions. Progression from a borderline ovarian tumors to low grade serous 
carcinoma commonly includes activating mutations in one of the following members of the MAPK 
pathway: KRAS, BRAF, or ERBB2. 
Figure 1. Classification of the Epit eli l ri c r istological subtype according to the two
tier system. Type I tumors include endometroid, clear cell carcino a, mucinous, and low grade
serous. Type II tumors are mostly comprised of high grade serous but also include carcinosarcoma and
undefined carcinomas [5,15,18,20].
Low grade serous, mucinous, endometrioid, and clear cell carcino as fall ithin the Type
I classification [5]. These tumors arise from endometrial tissue, fallopian tube tissue, germ cells,
and transitional epithelium [5,14,15,18,21,22]. Type I tu ors gro ore slo ly (are indolent) and are
considered to be more genetically stable [5,14,20]. Type II tumors typically have a higher disease volume
throughout the peritoneal cavity and a higher incidence of ascites than Type I tumors [20]. They appear
to follow a stepwise pattern from a benign precursor to a malignancy with genetic changes in specific
cell signaling pathways [2]. Type I tumors are predominantly of non-serous type [10]. Low grade serous
ovarian cancer accounts for approximately 5–10% of all serous ovarian cancers [2,10,16]. The most
common pathway disrupted in low grade serous ovarian cancer is the mitogen-activated protein kinase
(MAPK) pathway [5,6,16,17]. Specifically, activating mutations in BRAF and KRAS are common [2,10,23].
An active MAPK pathway is found in 80% of low grade serous tumors as well as in 78% of their putative
precursor lesions (borderline tumors) [16]. Other genes/pathways that are commonly altered in Type I
tumors include PTEN, PI3K, ARID1A, Wnt/β-catenin, and ERRB2 [2,6,15,18,20,24,25] (Figure 2).
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Figure 2. Pathway for Type I tumor formation. Type I tumors appear to form in a stepwise manner
from benign precursor lesions. Progression from a borderline ovarian tumors to low grade serous
carcinoma commonly includes activating mutations in one of the following members of the MAPK
pathway: KRAS, BRAF, or ERBB2.
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Prognosis for early-stage tumors is good with a >80% 5-year survival rate with chemotherapy [9].
When dividing all ovarian tumors between stages, Type I tumors are heavily represented in stage
I/II (clear cell, 26%; endometrioid, 27%; mucinous, 8%). Only about 36% of early stage tumors are
serous [18]. Treatment options for Type I ovarian tumors are identical to those used for Type II
tumors and include debulking surgery followed by chemotherapy [17,18]. The response of Type I
tumors to chemotherapy is poor due to the relative insensitivity to drug regimens and lack of targeted
therapies [7,26]. Low grade serous ovarian tumors have a low response rate to platinum-based
therapies with 4% showing a complete response, none with a partial response, 88% with stable disease,
and 8% with progression [27]. Another study demonstrated that low grade serous tumors are less
responsive than HGS tumors to both paclitaxel (69% vs. 14%) and carboplatin (50% vs. 17%) [27,28].
Type I tumors account for only 10% of ovarian cancer deaths [20]. The poor response of Type I
tumors to therapy and the chemoresistance that arises in Type II tumors highlight the need for novel
treatment strategies.
HGS tumors comprise 75% of all Type II tumors [3]. HGS neoplasms are typically aggressive
and develop rapidly (high mitotic activity) [5,18,20]. Previously, it was thought that HGS ovarian
cancer was derived from the ovarian surface epithelium or from cortical inclusion cysts [18,29].
Recent molecular and mouse studies suggest that these tumors likely arise from the epithelium of the
distal fallopian tube and that serous tubal intra-epithelial carcinoma (STIC) lesions are the precursors to
HGS ovarian cancer [29–31]. One study examined histological sections from fallopian tubes of ovarian
cancer patients for evidence of STIC lesions. STIC lesions were identified in 61% of the fallopian
tubes from HGS patients with 92% of the lesions being in the fimbriated end of the fallopian tube [32].
Kroeger et al. compiled a list of 15 studies showing that approximately 50–60% of HGS tumors are
associated with STIC lesions in the fimbriated end of the fallopian tube [3]. Furthermore, in a molecular
profiling analysis, HGS tumors with and without STIC lesions exhibited molecular profiles similar
to fallopian tube epithelium [29]. To establish if HGS ovarian cancer can be recapitulated in the
mouse, transgenic mouse models have been developed. Dicer and PTEN were conditionally deleted in
the reproductive tract using anti-Müllerian hormone receptor type 2-directed Cre (Amhr2-Cre) [33].
These mice exhibited abnormal proliferation in the stromal compartment of the fallopian tube [33].
Primary and metastatic tumors that developed in the mice were histologically serous carcinoma,
and they shared a similar gene expression profile with human HGS tumors [33]. In another model,
Pax8-Cre was used to drive the deletion of Brca/Pten/Tp53 in the fallopian tube. These mice developed
STIC lesions and serous carcinomas [31]. Interestingly, loss of PTEN alone in the fallopian tube
(via Pax-8-Cre) was sufficient to generate endometrioid and serous borderline tumors [34]. This raises
the possibility of fallopian tube origins for some Type I tumors and non-HGS tumors. While it is
possible that a portion of HGS tumors arise from the ovarian surface epithelium, it is likely that a major
site of origin for HGS tumors is the fallopian tube [30,35].
Unlike Type I tumors, there is a significant amount of genetic instability within the Type II
subgroup, and few genes are consistently mutated [5,14]. The main exception is that in Type II
tumors, TP53 mutations are common (both inactivating and gain of function) [36,37]. TP53 mutations
are rare in Type I tumors [6]. Type II tumors often exhibit active DNA damage repair mechanisms
(e.g., PARP) [3,20]. Overexpression of oncogenes ERRB2 (20–67%) and AKT (12–30%) also occur in
some cases [6]. Other common mutations in Type II tumors are BRCA1 or BRCA2. Epithelial ovarian
cancer is sporadic in 90% of cases with the remaining 10% being hereditary [2]. In 90–95% of hereditary
Type II ovarian tumors, there are germline mutations in BRCA1 or BRCA2 [2]. Importantly, BRCA1 and
BRCA2 are often mutated or inactivated in spontaneous ovarian cancer. BRCA1 and BRCA2 mutations
are detected in around 5–9% and 3–4% of spontaneous ovarian cancer, respectively [38–42]. Loss of
BRCA function through other means, particularly promoter methylation, is common in ovarian cancer
(particularly when mutations are not present) [43,44]. Therefore, the p53 and BRCA1/2 pathways are
highly implicated in development of HGS ovarian cancer.
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Most Type II tumors are found in advanced stages of the disease, which leads to a poor overall
prognosis. While Type II tumors respond well to chemotherapy (70–80%) initially, almost all patients
relapse and Type II tumors result in 90% of all deaths from ovarian cancer [20]. The advanced
stage of disease and development of chemoresistance with Type II tumors results in high mortality.
A contributing factor to tumor metastasis and chemoresistance is the presence or enrichment of
tumor-initiating/cancer stem cells (CSCs) [45]. Devising new treatments that eliminate this cell
demographic is of particular interest for HGS ovarian cancer.
3. Definition of Ovarian Cancer Stem Cells
Heterogeneity is a common feature in ovarian cancer tumors. Different models are proposed
to explain tumor heterogeneity. In the stochastic or clonal model, tumors arise from a group of
homogeneous cells (clonal). Tumor heterogeneity then occurs through random (stochastic) events
within this population. Any of the cells within this population can be tumor initiating provided they
possess the necessary genetic mutations, epigenetic changes, and a receptive microenvironment [46–50].
The second model (CSC model) recapitulates the stem cell hierarchy found in development of tissues
like the hematopoietic system. In this model, tumors are made of groups of heterogeneous cells that all
arise from precursor cells with stem-like properties. These “stem-like” precursors differentiate and/or
acquire different mutations that lead to diverse activation of pathways. The resultant cells have unique
phenotypes and a hierarchical pattern of inheritance from the initiating CSCs [47,49–52] (Figure 3).
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Figure 3. Models of tumor development and heterogeneity. (A) The clonal evolution model for tumor
initiation. A genetic event occurs in a cell giving rise to a mutant cell population. Any cell is capable of
becoming a tumor cell if there is an initiating genetic event. Tumor heterogeneity is due to propagation
of cells carrying mutations that are the result of multiple genetic events. (B) The cancer stem cell model
for tumor initiation. Either a normal stem cell has a genetic event resulting in a cancer stem cell capable
of indefi ite self-renewal and/or differentiation or a differentiated cell has a genetic event that activates
a stem like prog am wit in the cell r sulting in a cancer stem cell. Tumor cells have a hierarchical
inheritance pattern rom their cancer stem cell but dev lop different phenotypes as they acquire further
mutations as they differentiate resulting in tumor heterogeneity.
Cancers 2018, 10, 0241 6 of 23
Normal stem cells divide asymmetrically, allowing for self-renewal. One daughter cell retains
all the characteristics and programing of the parent cell while the other daughter cell differentiates
or acquires new properties [53]. To maintain their undifferentiated state and the ability to self-renew,
stem cells reside in a “stem cell niche” comprising various stromal cells, vascular support, and soluble
factors that provide a permissive environment [49,54]. CSCs display self-renewal characteristics and
retain the ability to produce cells that are highly proliferative and invasive [47,53]. Other characteristics
of CSCs include significant DNA repair capability and resistance to therapy [49,53]. In fact,
ovarian CSCs (CD133+ and Sca1+) persisted following chemotherapy in a mouse model of ovarian
cancer and in cells treated with carboplatin in vitro [45,55]. Moreover, these cells express stem cell
markers and maintain tumor initiating potential [45]. Additionally, in vitro studies demonstrated that
treatment of ovarian cancer cells with chemotherapy enriches the stem cell pool [56–58]. These studies
imply that CSCs are protected from chemotherapy and may be initiators of tumor relapse.
4. Stem Cell Identification in Ovarian Cancer
In 2005, Bapat et al. described the first example of a putative ovarian CSC. A single cell
was taken from the ascites of an ovarian cancer patient. Once propagated, the cell was able to
form anchorage-independent spheroids in culture and was able to seed tumors in mice via serial
transplantation over several generations, illustrating the stem-like capabilities of the cell [59]. Since this
initial study, many other investigations have been conducted to identify and validate ovarian CSCS.
Identification of CSCs relies on the presence of markers (cell surface and intracellular) that are unique
to this particular subset of tumor cells [46,47,50]. In ovarian cancer, a variety of markers are used to
denote the presence of CSCs. Cells isolated based on these markers can be tested for “stemness” in vitro
via spheroid forming assays, resistance to chemotherapeutics, and in vivo with limiting dilution assays
(LDAs) to examine the tumorgenicity of the sample [52]. In the LDA, mice are injected with a defined
number of cells from a mixed population of cells or cells isolated that express the stem cell markers.
The population that is more stem-like will initiate tumors from significantly fewer cells [60]. Table 1
contains a list of some putative ovarian CSC markers.
Table 1. Putative Ovarian Cancer Stem Cell Markers.
Marker Type of Protein Suspected Role in Stem Cells References
CD24 Cell surface transmembrane glycoprotein Stem gene expression, tumor initiation,chemoresistance, stem cell maintenance [46,53,61,62]
CD44 Cell surface transmembrane glycoprotein(hyaluronic acid receptor)
Chemoresistance, tumor initiation, stem gene
expression, spheroid formation [13,46,53,61–67]
cKit/CD117 Tyrosine kinase receptor Chemoresistance, stem cell maintenance,tumor initiation [11,53,59,61,68,69]
PROM1/CD133 Cell surface transmembrane glycoprotein Tumor initiation, chemoresistance,spheroid formation, high cell proliferation [13,46,53,61,62,70–76]
ALDH1 Cytosolic aldehydedehydrogenase enzyme
Tumor initiation, chemoresistance,
spheroid formation [46,53,61,75,77,78]
ROR1 Tyrosine kinase receptor Spheroid formation, tumor initiation,proliferation [79,80]
SOX2 Transcription factor Stem cell maintenance, self-renewal [8,81–84]
NANOG Transcription factor Stem cell maintenance, self-renewal,chemoresistance [8,53,61,66,81–83]
POU5F1/OCT4 Transcription factor Tumor initiation, chemoresistance [8,53,61,81–83]
MYC Transcription factor Tumor initiation, chemoresistance [85,86]
EpCAM Cell surface membrane glycoprotein Tumor initiation, spheroid formation,proliferation [13,46,53,61,62]
MDR1/ABCB1 ATP binding cassette transporter Chemoresistance [46,49,53,61,66,87–91]
ABCG2 ATP binding cassette transporter Chemoresistance [46,49,53,61,87,88,90,91]
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4.1. Side Population
One way in which ovarian CSCs are identified is by their ability to efflux DNA-binding
dyes such as Hoechst 33342 and Rhodamine 123 resulting in a side population (SP) using flow
cytometry. The ability to efflux these dyes identifies a CSC population that overexpress ATP
binding cassette transporters such as MDR1/ABCB1 and ABCG2 that can efflux chemotherapeutic
agents [46,49,61,87,88]. This SP demonstrates stem cell properties including the ability to repopulate
tumors in an LDA and resistance to chemotherapy. Expression of ABCB1 and ABCG2 correlates with
resistance to cisplatin and paclitaxel in ovarian cancer cell lines (2008, KF28, TU-OM-1, OVCAR3,
SKOV3) and in cells from patient and mouse ascites [89–91]. However, the SP of cells is heterogeneous
and can display different combinations of other stem cell markers, so it may be unknown which cells
within this population is most “stem-like” or which population(s) are reconstituting the tumor [53].
4.2. Cell Surface Markers
Cell surface makers are essential in the identification of CSCs for multiple tumor types.
When Bapat et al. first described ovarian CSCs, CD117 was demonstrated to be a cell surface marker
for the ovarian CSCs [59]. Human serous ovarian cancer patient-derived xenografts (PDXs) showed
that CD117+ cells isolated from the xenografts were able to recapitulate a tumor with only 10,000 cells;
this was a 100-fold increase in tumor initiating capability compared with the CD117− cells [68].
CD117+ cells were also successful at generating tumors when serially transplanted [68]. Other ovarian
CSC surface markers include CD24, CD44, EpCAM, and CD133 [13,46,53,61,62]. One of the most
commonly reported ovarian CSC markers is CD133. CD133 expression correlates with poor prognosis
in ovarian cancer and increased chemoresistance [70–72]. In cell lines, CD133 promotes a number
of stem characteristics. CD133+ and CD133− cells were single cell isolated and expanded from
A2780 and PEO1 cell lines [73]. The CD133− cells only produced CD133− cells while CD133+ cells
divided asymmetrically to produce both CD133+ and CD133− cells, suggesting that the CD133+ cells
retain stem cell properties [73]. CD133+ cells exhibit increased resistance to cisplatin and were more
tumorigenic in xenograft and serial transplantation studies [73,74]. Another one of the common CSC
markers is CD44. CD44 is the hyaluronate receptor and is important in adhesion. In ovarian cancer,
CD44 correlates with chemoresistance and tumor progression [63–65]. One function of CD44 is to
activate Stat3 [66]. CD44 is commonly used as a stem cell marker in combination with CD117, MyD88,
E-cadherin/CD34, and CD24/EpCAM. Each of these CD44+ cell populations has been demonstrated
to have stem-like properties (reviewed in Klemba et al.) [67]. In conclusion, there are multiple surface
markers used to identify CSCs in ovarian cancer. Some investigations use these surface markers alone
or in combination with other markers. However, we are still uncertain if there is a definitive ovarian
CSC marker/population, if multiple CSC populations co-exist, or if CSC identity varies by patient.
4.3. ALDH Activity
In addition to cell surface markers, CSCs often are identified using the expression of the enzyme
aldehyde dehydrogenase 1 (ALDH1) and its activity. The enzymatic activity of ALDH1 is used to
identify and define CSCs in cancer types including breast, colon, liver, and ovarian [46]. Several studies
suggest that ALDH1 expression correlates with poor prognosis. In one study of ovarian cancer
patients, ALDH1A1 expression was found in 72.9% of tumors, and this expression correlated with
decreased progression-free survival (6.05 vs. 13.81 months) [77]. A second study demonstrated that
patients with high ALDH1 expression (by immunohistochemistry in >50% of the tumor section)
exhibited poorer prognosis [78]. Cell lines with high ALDH1 exhibited increased chemoresistance and
tumorgenicity [78]. Silva et al. examined 13 primary human ovarian tumors and 5 ascites samples
for various putative CSC markers. ALDH1 was expressed in all cases [75]. Ovarian cancer cell
lines were then examined for these CSC markers. Each of the cell lines examined (A2008, SKOV3,
HEY-1, A2780, OVCAR8, OVCAR3, and OVCAR432) had a subpopulation of cells with ALDH1
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expression [75]. Conversely, knockdown of ALDH1A1 in an orthotopic mouse model (from both
taxane- and platinum-resistant cell lines) sensitized the tumors to treatment, resulting in reduced
tumor growth [77]. The expression and activity of ALDH1 alone or in combination with cell surface
stem cell markers is a popular and accepted method for identifying ovarian CSCs.
4.4. Transcription Factors
Pluripotency transcription factors necessary for normal stem cell maintenance are commonly
expressed in ovarian CSCs [53,81–83]. In addition to being markers for ovarian CSCs,
transcription factors such as OCT4, SOX2, and NANOG are expressed during development and
are essential for normal stem cell maintenance and proliferation [62,66,84,92–95]. Aberrant expression
of stem cell genes in differentiated cells, progenitor cells, or stem cell populations can lead to enhanced
self-renewal and proliferative capability [96]. Expression of stem cell transcription factors not only
provides evidence for the CSC model of tumor development, it also explains in part how stem cell
properties of self-renewal and asymmetric division are maintained in CSCs. By comparing normal
stem cell populations to CSCs we can gain insight into tumor initiation and regulation of the CSC
phenotype. In embryonic stem cells (ESCs) the pluripotency transcription factors form a protein
interaction network [83]. Many of these interactions are critical for stem cell functions. In addition,
expression of pluripotency factors and protein–protein interactions are retained in CSCs. Among these
factors is ARID3B. ARID3B and its paralog ARID3A are expressed in ESCs in a complex with NANOG,
OCT4, and NAC1 [83]. ARID3B is overexpressed in serous ovarian cancer and its expression in
the nucleus correlates with relapse following chemotherapy [58,97]. ARID3B increases expression
of stem cell markers [76]. In particular, ARID3B induces expression of the stem cell marker Prom1
(CD133) [58]. ARID3B additionally increases the pool of CD133+ cells, suggesting that it has a role
in promoting a stem cell phenotype [58,76]. In fact, ARID3A and ARID3B co-localize with CD133 in
ovarian cancer tumor sections. Additionally, ARID3B is enriched in ovarian cancer ascites sorted for
CD133+ cells (Figure 4). These data suggest that ARID3B+ cells are found in a stem cell niche (Figure 4).
Future studies on pluripotency factors common in ovarian CSCs including OCT4, MYC, and ARID3B
will provide clarity for how cancer stemness is maintained [85,86].
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Different stem cell markers may confer different selective advantages to different pools of “CSCs”.
Patients may have more than one pool of stem cells and different patients may have CSCs with different
phenotypes. An example is included in Figure 5. To enrich for CSCs, OVCA429 and Kuramochi cells
were untreated or treated with cisplatin and paclitaxel and then cultured on nonadherent plates in
stem cell media [56]. Flow cytometry was performed for CD117 (gene = CKIT) and CD133. OVCA429
cells have a clear CD117+CD133− population of CSCs that is enriched following chemotherapy
treatment. Following chemotherapy treatment, multiple cell populations are expanded in Kuramochi
cells including CD133+/CD117−, CD133+/CD117+, and CD117+/CD133−. These experiments suggest
that different stem cell pools may be more prevalent in an individual cell type or patient tumor.
Importantly, each of the CSC markers may have its own each unique function. The kinase activity of
CD117 may provide a survival advantage over CD117− cells [69]. However, CD133+ cells may have
an adhesion or metastatic advantage over cells lacking CD133 [76]. Although we can detect cell-to-cell
variation in the expression of markers, we do not know if these different CSC lineages arise from
common progenitors. CSC lineage tracing to define the hierarchy of cells in a stem cell population has
not been conducted for all putative ovarian CSC subtypes. Additionally, LDAs need to be conducted
to verify stem cell potential for each putative ovarian CSC population. In order for studies of CSCs to
be translational, we will need to define how the different CSC populations pertain to patient prognosis,
relapse, and response to therapy. Moving forward, we need to establish the clinical significance of
different ovarian CSC marker profiles [47,52,53,61,99]. Comparing survival and relapse potential for
patients based on these different marker profiles is essential for us to develop effective treatments for
the clinically relevant ovarian CSC populations.
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univariate and multivariate analysis show that high expression of activated AKT (pAKT) is associated
with poor progression-free survival and poor overall survival [102]. Due to mutations in many parts
of the PI3K/PTEN/AKT pathway, activated AKT signaling is highly relevant for ovarian cancer
development and progression.
The PI3K/PTEN/AKT pathway is also implicated in ovarian CSCs. PI3K/PTEN/AKT signaling
regulates enrichment of CSCs, maintenance of a CSC phenotype, and chemoresistance [103–106].
Spheroids derived from SKOV3 and HO8910 cell lines expressed elevated phosphorylated AKT1 and
decreased expression of PTEN [103]. The spheroids exhibited increased resistance to paclitaxel [103].
Conversely, inhibiting AKT1 activation decreased spheroid formation and migration [104]. Knockdown
of AKT1 via siRNA resulted in the loss of CSC marker expression (OCT4, SOX2, ALDH1, and ABCG2)
as well as loss of spheroid formation and paclitaxel resistance [104]. These studies demonstrate the
importance of the PI3K/PTEN/AKT pathway in CSC formation, maintenance, and chemoresistance
to paclitaxel.
The PI3K/PTEN/AKT pathway also regulates cisplatin resistance in ovarian cancer.
In cisplatin-resistant A2780 cells (A2780-CP), AKT regulates the expression of PPM1D [105].
PPM1D inhibits the DNA damage and apoptotic response after DNA damage occurs [105].
Downregulation of AKT activity results in loss of PPM1D stability and increases its degradation [105].
Loss of PPM1D increases the response of the A2780-CP cells to cisplatin [105].
The PI3K/PTEN/AKT signaling pathway promotes the enrichment of ovarian CSC populations
and regulates ovarian CSC chemoresistance, thus making it an ideal target for therapeutics to
eliminate ovarian CSCs. There are currently PI3K/PTEN/AKT inhibitors such as BKM120, Everdimus,
and Perifosine that are being used to treat cancer patients [100]. Future efforts to stratify patients that
are likely to benefit from PI3K/PTEN/AKT inhibition will be needed for this therapy to be effective in
ovarian cancer patients.
5.2. Jak2/STAT3
Proliferation, survival, and differentiation are all regulated by the Jak2/STAT3 pathway in
several solid tumors [107]. In ovarian cancer, the Jak/STAT pathway is constitutively active in
most cases [108]. Jak/STAT is implicated for having a key role in the development of HGS ovarian
cancer. Activation of STAT3 via phosphorylation at Tyr705 and the loss of the STAT3 inhibitor PIAS3
may serve as a tumor-initiating event in the distal fallopian tube for the formation of HGS ovarian
cancer [109]. Phosphorylated STAT3 is expressed in 86% of ovarian tumors examined (from different
histotypes) and constitutive pSTAT3 expression is expressed in 63% of the HGS tumors examined [110].
Phosphorylated, nuclear STAT3 is associated with poor prognosis [110]. In tissue microarrays (TMAs),
patients whose tumors had high nuclear pSTAT3 staining (>10% nuclei stained) had poorer survival
rates than women with low nuclear pSTAT3 staining (<10% nuclei stained) [110]. These patient
findings implicate the Jak/STAT pathway as being highly important for ovarian cancer initiation
and progression.
The Jak/STAT pathway also regulates ovarian CSCs. CD24+ ovarian CSCs require Jak2/STAT3
signaling for growth and metastasis [111]. Primary tumors generated in the Apc−; Pten−; Trp53−
(transgenic mouse model in which APC, PTEN, and Trp53 are conditionally deleted in the ovarian
surface epithelium) were collected, dissociated, and sorted via fluorescence-activated cell sorting
(FACS) using stem cell markers [111]. LDAs confirmed that the CD24+ cells isolated were a CSC
population [111]. This population of cells expressed elevated pSTAT3 and stem cell marker NANOG,
which is required for stem cell renewal [111]. CD24+ cells were injected into mice and the mice
were then treated with cisplatin or with cisplatin+TG101209, a Jak2 inhibitor [111]. The mice
treated with cisplatin+TG101209 showed significantly increased survival and almost no metastases
(1 out of 14) [111].
Other studies show a role for the Jak/STAT pathway in ovarian CSC maintenance and
chemoresistance. Abubaker et al. collected tumor cells from patient ascites or the HEY8 ovarian
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cancer cell line and treated them with paclitaxel [108]. Treatment with paclitaxel induced the
expression of CSC markers CD117, OCT4, and EpCAM in ascites and HEY8 cells [108]. In both the
paclitaxel-treated ascites and HEY8 cells, the Jak2/STAT3 pathway was activated [108]. This suggests
that the Jak2/STAT3 pathway regulates the expression of stem-like genes necessary for CSC
maintenance. Moreover, paclitaxel-treated cells were also treated with the Jak2-specific small molecule
inhibitor (CYT387), which resulted in inhibition of the Jak2/STAT3 pathway activation, loss of
stem cell marker expression, and increased sensitivity of the cells to paclitaxel treatment [108].
When paclitaxel-treated and paclitaxel+CYT387-treated cells were injected into mice, the mice injected
with the paclitaxel+CYT387-treated cells showed a reduced tumor burden and enhanced sensitivity
to paclitaxel [108]. These studies demonstrate that in models of ovarian cancer, Jak2 inhibitors are
effective at reducing stem cell characteristics and inhibiting tumor growth. These inhibitors also
increase survival and response to therapy. Because the Jak/STAT pathway promotes stemness and
chemoresistance in the CSC population, it is a viable target for therapies aimed at reducing ovarian
CSC populations.
5.3. NFκB
The NFκB pathway plays a role in normal cellular processes such as survival, proliferation,
and apoptosis. In cancer the NFκB pathway is implicated in invasion and metastasis.
However, the pathway is also involved in CSC maintenance [112]. In ovarian cancer, both the
canonical and noncanonical NFκB pathways are active. A CD44+ ovarian CSC population isolated
from patient ascites exhibited constitutive NFκB pathway activation via a luciferase reporter assay,
formed spheroids in culture, and formed tumors when injected into mice [13]. Another study showed
that CD44+ CSCs from SKOV3 cells (that also express NANOG, SOX2, and OCT4) exhibited increased
expression of NFκB pathway members RelA, RelB, and IKKα [113]. Inhibition of the NFκB pathway
with a dominant-negative form of IκBα resulted in a decrease in the CD44+ CSC population with
a reduction from 65.3% CD44+ cells to just 27.7% [113]. These data suggest that NFκB signaling
regulates expression of stemness genes.
The NFκB pathway is also involved in ovarian CSC chemoresistance. CD44+ ovarian CSCs
from patient ascites have constitutively active NFkB [13]. When treated with TNFα, the CD44+ cells
showed increased NFκB activity and cytokine production as well as resistance to TNFα-induced
apoptosis [13]. The resistance to apoptotic pathway activation suggests a mechanism for ovarian
CSC survival when treated with chemotherapeutics. Treatment of ovarian CSCs with Eriocalyxin
B (EriB) inhibits the NFκB pathway and induces cell death in ovarian CSCs [114]. EriB inhibited
the TNFα-induced NFκB activity and cytokine production and sensitized the cells to TNFα- and
FasL-induced cell death [114]. This suggests that inhibition of the canonical NFκB pathway could
sensitize ovarian CSCs to therapy [114].
While many studies focused on the canonical NFκB pathway, the noncanonical pathway is also
active in promoting stemness and chemoresistance in ovarian cancer. RelB in particular is important for
ovarian CSC regulation. RelB is overexpressed in ovarian CSC populations including CD44+ SKOV3
cells and ALDH+/CD133+ OV90 and ACI23 cell lines [113,115]. In the OV90 and ACI23 cells, ALDH1
activity and expression of RelB both increase with carboplatin treatment [115]. This suggests a role for
the noncanonical NFκB pathway and RelB in promoting stemness and chemoresistance. Knockdown
of RelB with shRNA reduced the number of ALDH+/CD133+ CSCs in vitro in both cell lines and
in xenografts by 50% [115]. The RelB knockdown decreased expression of other stem cell markers
(NANOG and CD44) and increased sensitivity to carboplatin [115]. In addition, ACI23 and OV90 cells,
when stably transfected with inducible shRNA for RelB, showed reduced spheroid formation and
reduced tumorgenicity [115]. The noncanonical pathway through RelB promotes tumor growth as well
as the expression of stemness genes [115]. RelB also regulates chemoresistance in ovarian CSCs [115].
Thus, both the canonical and noncanonical NFκB pathways are excellent targets for therapeutics to
reduce the CSC population.
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5.4. Notch
Notch signaling has a role in multiple cellular processes. Notch is a critical component
in regulating progenitor cell maintenance, differentiation, cell proliferation, and apoptosis.
Notch is also important for cell–cell communication [116,117]. In HGS ovarian cancer, Notch3
expression is amplified/overexpressed [118]. By analyzing 31 fresh HGS ovarian cancer samples,
Notch3 amplification correlated with protein expression [118]. Notch3 was overexpressed more often
in high grade tumors (66%) than in low grade tumors (33%) [118]. Further, according to The Cancer
Genome Atlas (TCGA), Notch3 is amplified in 17% of HGS tumors. The most highly expressed Notch3
ligand in ovarian serous carcinoma is Jagged 1, which is predominantly expressed in the mesothelial
cells within the tumor microenvironment, suggesting a role for Notch3/Jagged 1 signaling in cell
adhesion and proliferation [119].
In the majority of patients with recurrent HGS ovarian cancer, Notch3 is overexpressed [120].
Tumors from patients with either primary disease or recurrent disease were examined for Notch3
overexpression and survival [120]. In the group with primary disease, there was no difference in
survival between those with Notch3 overexpression and those without [120]. Those in the group with
recurrent disease did show a difference. Those expressing high Notch3 levels had decreased overall
survival (22 vs. 37 months) and decreased progression-free survival (3 vs. 8 months) suggesting that
Notch3 expression is a factor in the recurrence of ovarian cancer as well as a prognostic indicator in
recurrent disease [120].
Chemoresistance is a hallmark of CSCs and disease recurrence/relapse, and Notch3 expression
affects the expression of stemness factors as well as chemoresistance. The transcription factor
OCT4 promotes self-renewal of ovarian CSCs while SOX2 is required for their maintenance [84,92].
Overexpression of Notch3 in ovarian cancer cell lines (IOSE-80pc and MPSC1) enhances expression of
stem cell markers (NANOG, OCT4, and SOX2) and increases expression of the ABCB1 transporter
protein [120]. The ABCB1 transporter increases chemoresistance in these ovarian CSCs and NANOG
promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer [121]. To demonstrate
the role of Notch3 on chemoresistance, Nocth3 was knocked down in OVCAR3 cells using shRNA
resulting in reduced IC50 compared to control cells [120]. These studies all implicate Notch3 signaling
in ovarian CSC chemoresistance.
Other Notch signaling molecules are also implicated in stemness and chemoresistance including
Jagged 1 and downstream signaling molecules. Downregulation of Jagged 1 in SKOV3TRip2 cells
via siRNA increased sensitivity of cells to docetaxel [122]. In ovarian cancer cells isolated for the
SP, Notch pathway genes (FPTG, ST3GAL6, and ADAM19), stem cell markers NANOG and OCT4,
and three ABC transporter genes (ABCG2 [both lines], ABCC4 [SKOV3 only], and ABCB1 [A224 only])
were induced [95]. Collectively, the data suggest that Notch signaling is involved in promoting
stemness and chemoresistance, and expression of Notch3 in particular may serve as a prognostic
indicator for patients with recurrent disease. Notch signaling is an attractive target for therapeutics
aimed at ovarian CSCs. Currently, there are experimental γ-secretase inhibitors, γ-secretase modifiers,
Notch soluble decoys, and negative regulatory region monoclonal antibodies that are already being
developed [116].
5.5. Wnt
Wnt signaling is particularly important during development where it regulates cell fate
determination during embryogenesis including the cardiovascular system, central nervous system,
and craniofacial development [116,123]. In adults, Wnt signaling is critical for self-renewal in tissues
(e.g., bone growth plate, hair follicles, colon, etc.) [116,124,125]. The major processes regulated by
noncanonical Wnt signaling include cell polarity and motility; however, Wnt also plays a role in
maintaining stem cells, quiescence, and chemoresistance [126]. Wnt signaling is complex and many
components of Wnt signaling are implicated in ovarian CSCs and chemoresistance (Figure 6).
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With regards to ovarian cancer, Wnt signaling is involved in normal development of the ovarian
and fallopian tube stem cells. Wnt signaling also has functions in tumor development. LGR5 is a stem
cell marker for ovarian stem cells and LGR6 is a stem cell marker for the fallopian tube, and expression
of either one is a sign of elevated Wnt signaling [127–129]. LGR5 and LGR6 are expressed in HGS
tumors [127]. LGR5+ cell-driven lineage tracing was performed in mice, illustrating the importance of
LGR5 and Wnt signaling in embryonic and adult ovarian stem cells for homeostasis and regenerative
repair and self-renewal [130]. Since the fimbria of the fallopian tube are implicated as a site of origin
in HGS tumors, fallopian tube stems cells also must be examined [129]. Using a Tcf-eGFP reporter
and confocal microscopy on fallopian tube organoid cultures, active Wnt signaling was needed for
the expression of stem cell factors to support organoid growth [129]. Understanding how abnormal
regulation of Wnt signaling drives initiation or maintenance of ovarian CSCs is critical.
Disregulation of Wnt signaling is frequently involved in the development of cancer [123,131].
In ovarian cancer, aberrant Wnt signaling differs by histotype. Wnt signaling stabilization and
subsequent nuclear translocation of β-catenin leads to activation of Wnt target genes including those
involved in stemness. β-catenin is frequently mutated at GSK3β phosphorylation sites that allow
β-catenin to be ubiquinated and degraded in the absence of Wnt signaling (54%) resulting in nuclear
localization in approximately 70% of cases of low grade endometrioid ovarian carcinomas [132].
Activating mutations of proteins in the Wnt pathway are rare in serous ovarian carcinomas [132].
However, there is evidence of nuclear β-catenin in HGS [132]. With regards to the noncanonical Wnt
pathway, Wnt5A was highly expressed in a collection of 583 ovarian tumors and it is found in the
ascites [126,132]. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) (a pseudokinase and receptor
for Wnt5A) is expressed in ovarian cancer and is correlated with poor outcomes [79]. Survival analysis
showed that patients with high expression of ROR1 had significantly reduced progression-free survival
and overall survival [79]. Cells isolated from ROR1+ patient-derived xenografts exhibited stem-like
qualities including ALDH1 expression, ability to form spheroids, and increased tumorgenicity [80].
These data suggest that ROR1 is a potential CSC marker for ovarian cancer and that noncanonical Wnt
signaling is a component of ovarian cancer stemness.
In ovarian CSCs, Wnt signaling helps promote both stemness and chemoresistance. The CSC
marker/receptor tyrosine kinase, CD117, is upregulated in ovarian CSCs. Many factors contribute to
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acquisition of CD117 expression including the hypoxic microenvironment of the stem cell niche [106].
CD117 leads to activation of AKT and the phosphorylation of GSK3β and nuclear expression of
β-catenin [106]. β-catenin activity induces expression of ABCG2, a drug transporter which increases
cisplatin and paclitaxel resistance [106]. Therefore, the hypoxic niche supports stemness by activation
of Wnt target genes.
Wnt signaling in ovarian cancer CSCs is complex. Collectively, the patient studies combined with
cell culture and animal models suggest that multiple Wnt signaling pathways contribute to stemness
and chemoresistance in ovarian cancer. A number of potential molecules in the Wnt pathways
may be viable targets for therapeutic intervention. Wnt inhibitors such as compounds that target
Disheveled (NSC668036 and FJ9), Frizzled receptor antibody, Thiazolidinedione (target β-catenin
reverse transport), and Sulindac (unknown action but potentially effects β-catenin proteasomal
degradation) are being examined for use in cancer treatment [116]. Deciphering the cross-talk between
Wnt and other pathways in addition to more sophisticated assessment of the contribution of particular
Wnt molecules and pathways will enable development of future Wnt-targeted drugs that can be used
in ovarian cancer treatment.
5.6. Hedgehog
During embryogenesis, Hedgehog signaling (Hh) regulates tissue polarity as well as patterning
and stem cell maintenance [116]. In cancer, the Hh pathway is dysregulated in one of two ways:
(1) constitutive expression of endogenous ligand (e.g., Sonic hedgehog [Shh]) or (2) mutations of
proteins within the pathway (Patched, SMO, SUFU) [133]. We will explore the ways Hedgehog
signaling has emerged as an important regulator of proliferation, chemoresistance, and stemness in
ovarian cancer [133,134].
Overexpression of Gli1 (a transcription factor activated by Hh signaling) as well as PTCH
(Hh receptor) is correlated with poor prognosis and survival in patients [133]. Eighty cases of epithelial
ovarian tumor were examined by IHC [133]. All cases expressed PTCH, though PTCH was highly
expressed in 34.1% of cases [133]. Gli1 expression varied by histotype of the tumor with high Gli1
expression being most common in serous tumors [133]. High expression of either Gli1 or PTCH
correlated with poor survival compared to those patients with low expression [133]. These data
suggest that Gli1 and/or PTCH expression may be prognostic indicators for ovarian cancer patients.
Gli1 antagonists such as HPI 1–4 that are currently being developed as well as drugs targeting PTCH
may be useful therapies for ovarian cancer patients with activated Hh signaling.
In ovarian cancer, Gli1 appears to be a critical contributor. Gli1 is a regulator of proliferation
and tumor growth in ovarian cancer. Gli1 is elevated in several ovarian cancer cell lines (OVCAR5,
OV-202, and OV-167) compared with normal ovarian surface epithelium [135]. Inhibition of the Hh
pathway with cyclopamine resulted in Gli1 decreasing in a dose-dependent manner (60–80%) [135].
The decrease in Gli1 mRNA and protein correlated with a decrease in proliferation in all three cancer
lines [135]. In addition to the in vitro results, a mouse xenograft model using OVCAR5 cells found
that cyclopamine significantly inhibited tumor growth [135]. In agreement with these findings,
exogenous expression of Gli1 in ovarian cancer cell lines SKOV3, OVCAR3, and OVCA433 increased
cell proliferation 2-fold and increased invasiveness 200–500% over control; whereas knockdown of
Gli1 with siRNA suppressed proliferation and invasiveness (40–60%) [133]. These studies suggest that
Gli1 is an important regulator of proliferation and tumor growth in ovarian cancer.
The Hh pathway regulates stemness in ovarian cancer. In one study, ES2, SKOV3, and TOV112D
cells were treated with recombinant Shh and Ihh, both Hh pathway agonists [134]. In all three cell
lines, spheroid formation increased significantly [134]. When treated with cyclopamine, there was
significant impairment of spheroid formation [134]. This demonstrates a role for the Hh pathway in
maintaining stemness in ovarian cancer.
Gli1 also is implicated in chemoresistance in ovarian cancer cells. Gli1 has an interesting role
in the DNA damage response following cisplatin treatment [136]. In cisplatin-resistant A2780 cells
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(A2780-CP), cells with anti-Gli1 shRNA or a scrambled shRNA were treated with cisplatin and then
DNA repair was assessed [136]. After 12 h the control cells had repaired 78% of the DNA adducts
compared to 33% in cells treated with anti-Gli1 shRNA [136]. In addition to impairing the cell’s ability
to repair the cisplatin adducts, pretreatment with the anti-Gli1 shRNA sensitized the cells to cisplatin
resulting, in a shift of the IC50 from 30 µM to 5 µM [136]. This suggests that Gli1 regulates DNA
adduct repair and sensitivity to cisplatin in ovarian cancer. Additionally, Gli1, SMO, and PTCH are
overexpressed in borderline and malignant ovarian cancer [137]. Moreover, Gli1 and SMO were highly
overexpressed in platinum-resistant ovarian cancer [137]. Both cell culture and patient studies suggest
an important role for Gli1 and Hh signaling in ovarian cancer chemoresistance.
While Hh signaling is studied in regard to other cancer types, Hh signaling in ovarian cancer
is relatively understudied. Current findings suggest that Gli1 has an important role in ovarian
cancer stemness, tumorigenicity, and chemoresistance. Further studies on the role of Hh signaling
in ovarian cancer will allow for personalized medicine approaches for those patients with active Hh.
Future therapy options could include the Hh inhibitor GDC-0449 that is currently in clinical trials for
use in ovarian cancer [138].
5.7. Developing Therapeutics Targeting Ovarian Cancer Stem Cells
There are multiple pathways involved in promoting a stem cell phenotype and chemoresistance
in ovarian cancer. Each pathway has the potential to be therapeutically targeted. However, a major
challenge is defining which population of cells needs to be targeted with pathway inhibitors.
If a therapeutic goal is to eliminate the CSC population, more studies are needed to define CSC
populations, markers, and critical pathways that are required for stem cell maintenance (Table 2:
Summary of targetable genes).
Table 2. Summary of targetable genes.
Pathway Gene Potential Therapeutics in Trials
PI3K/PTEN/AKT
AKT1
BKM120, Everdimus, PerifosinePTEN
PPMID
Jak/STAT STAT3
JAK2
NFκB
RelA
RelB
IKK
IκBα
TNFα
Notch
Notch3 γ-secretase inhibitors, γ-secretase modifiers, Notch soluble decoys,
negative regulatory region monoclonal antibodiesJagged1
Wnt
β-catenin
NSC668036, FJ9, Frizzled receptor antibodies,
Thiazoldinedone, Suldinac
Wnt5A
Disheveled
Frizzled
Hedgehog Patched HPI-1, HPI-2, HPI-3, HPI-4, GDC-0449Gli1
6. Future Studies
Ovarian CSCs in HGS ovarian cancer are an attractive target for therapeutics in order to prevent
relapse following chemotherapy. Prior to targeting these insidious cells, a number of issues should
be considered. One complication in treating patients with HGS ovarian cancer is the amount of
heterogeneity found within the tumors. Additionally, HGS is characterized by genomic instability
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rather than specific driving mutations. This level of heterogeneity makes identifying drug targets
that help a wide population of HGS ovarian cancer patients difficult. More phenotypic, genetic,
and epigenetic studies of patient CSCs need to be conducted to assess which CSC populations are
the most critical ones to target. Hierarchical lineage tracing efforts will allow us to decipher if
different CSC populations arise from a common progenitor cell. Detailing the mechanisms that
are required for CSC maintenance is critical. Delineating the role of the microenvironment in CSC
maintenance is also important. Do these varying marker profiles denote differing niches for the CSCs
and, therefore, different survival and renewal pathways that are active in different populations of CSCs?
Are different CSC subpopulations present at different times during cancer progression? These questions
underscore the need for personalized medicine in the treatment of ovarian cancer. Three potential
targets for new therapeutics include stem cell markers, stem cell signaling pathways needed for
renewal and/or survival, and the stem cell niche. Careful studies examining the contribution of
CSC subpopulations and signaling pathways to CSC survival and maintenance will lead to directed
therapeutic target design.
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